Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivdak in recurrent or metastatic cervical cancer
NCT04697628Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of tisotumab vedotin in Cervical Cancer (CC), sponsored by Pfizer. Primary endpoint: Overall Survival at 25 months. Started Feb 2021; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04697628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697628.